<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523340</url>
  </required_header>
  <id_info>
    <org_study_id>MENTOR_2011</org_study_id>
    <nct_id>NCT01523340</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response</brief_title>
  <acronym>MENTOR</acronym>
  <official_title>Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Trial design: Prospective observational study&#xD;
&#xD;
        2. Target population: 200 NSCLC patients with histologically or cytologically confirmed&#xD;
           stage IV or recurrent NSCLC who have progressive disease after 1st line chemotherapy who&#xD;
           consent for study participation and meet the study selection criteria&#xD;
&#xD;
        3. Primary objective: To investigate C-met expression/amplification and EGFR gene mutations&#xD;
           in NSCLC patients treated with Erlotinib&#xD;
&#xD;
             -  C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR&#xD;
&#xD;
        4. We will also assess the correlation of EGFR mutations and c-MET with clinical outcome&#xD;
           (Overall Response Rate, Progression Free survival )&#xD;
&#xD;
        5. Duration of Trial Recruitment: 2 years&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rates of C-met expression/amplification and EGFR gene mutations</measure>
    <time_frame>Average of 1 year</time_frame>
    <description>To investigate C-met expression/amplification and EGFR gene mutations in NSCLC patients treated with Erlotinib&#xD;
: C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">196</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Erlotinib treatment</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      NSCLC tumor tissue for c-MET expression by immuohistochemistry c-MET amplification by silver&#xD;
      in situ hybridization EGFR mutation by realtime PCR&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically or cytologically confirmed stage IV or recurrent NSCLC who&#xD;
        have progressive disease after 1st line chemotherapy who consent for study participation&#xD;
        and meet the study selection criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  19~80 year old male or female&#xD;
&#xD;
          -  Histologically proven advanced or metastatic NSCLC&#xD;
&#xD;
          -  Failed to 1st line chemotherapy&#xD;
&#xD;
          -  Tumor tissue for genetic analysis&#xD;
&#xD;
          -  Evaluable target lesion by RECIST v1.1&#xD;
&#xD;
          -  ECOG performance from 0 to 3&#xD;
&#xD;
          -  Expected survival more than 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment of EGFR-tyrosine kinase inhibitors&#xD;
&#xD;
          -  Severe hypersensitivity to erlotinib&#xD;
&#xD;
          -  Residual toxicities (above grade 2) after previous chemotherapy&#xD;
&#xD;
          -  Total bilirubin more than 1.5x of upper normal limit Liver function tests more than&#xD;
             2.5x of upper normal limits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

